562 related articles for article (PubMed ID: 23947935)
1. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
Banchs JE; Baquero GA; Nickolaus MJ; Wolbrette DL; Kelleman JJ; Samii S; Grando-Ting J; Penny-Peterson E; Davidson WR; Young SK; Naccarelli GV; Gonzalez MD
Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
[TBL] [Abstract][Full Text] [Related]
2. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
McClellan KJ; Markham A
Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
Nørgaard BL; Wachtell K; Christensen PD; Madsen B; Johansen JB; Christiansen EH; Graff O; Simonsen EH
Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
[TBL] [Abstract][Full Text] [Related]
4. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
Wolbrette DL; Hussain S; Maraj I; Naccarelli GV
J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
Banchs JE; Wolbrette DL; Samii SM; Penny-Peterson ED; Patel PP; Young SK; Gonzalez MD; Naccarelli GV
J Interv Card Electrophysiol; 2008 Nov; 23(2):111-5. PubMed ID: 18688699
[TBL] [Abstract][Full Text] [Related]
6. Dofetilide: a new class III antiarrhythmic agent.
Roukoz H; Saliba W
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
[TBL] [Abstract][Full Text] [Related]
7. Use of dofetilide in adult patients with atrial arrhythmias and congenital heart disease: A PACES collaborative study.
El-Assaad I; Al-Kindi SG; Abraham J; Sanatani S; Bradley DJ; Halsey C; Law IH; Balaji S; Shetty I; Aziz PF
Heart Rhythm; 2016 Oct; 13(10):2034-9. PubMed ID: 27435587
[TBL] [Abstract][Full Text] [Related]
8. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
Singh SN
Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
Singh S; Zoble RG; Yellen L; Brodsky MA; Feld GK; Berk M; Billing CB
Circulation; 2000 Nov; 102(19):2385-90. PubMed ID: 11067793
[TBL] [Abstract][Full Text] [Related]
10. Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.
Khurshid S; Akerman S; Man JP; Supple G; Dixit S; Epstein AE; Marchlinski FE; Frankel DS
J Interv Card Electrophysiol; 2015 Mar; 42(2):117-24. PubMed ID: 25620152
[TBL] [Abstract][Full Text] [Related]
11. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Mykytsey A; Bauman JL; Razminia M; Zheutlin T; Wang T; Saleem M; Leal S; Kehoe RF
J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):36-43. PubMed ID: 17495256
[TBL] [Abstract][Full Text] [Related]
12. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
Torp-Pedersen C; Møller M; Bloch-Thomsen PE; Køber L; Sandøe E; Egstrup K; Agner E; Carlsen J; Videbaek J; Marchant B; Camm AJ
N Engl J Med; 1999 Sep; 341(12):857-65. PubMed ID: 10486417
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
Bianconi L; Castro A; Dinelli M; Alboni P; Pappalardo A; Richiardi E; Santini M
Eur Heart J; 2000 Aug; 21(15):1265-73. PubMed ID: 10924317
[TBL] [Abstract][Full Text] [Related]
14. Acute conversion of persistent atrial fibrillation during dofetilide initiation.
Cotiga D; Arshad A; Aziz E; Joshi S; Koneru JN; Steinberg JS
Pacing Clin Electrophysiol; 2007 Dec; 30(12):1527-30. PubMed ID: 18070309
[TBL] [Abstract][Full Text] [Related]
15. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
Coleman CI; Sood N; Chawla D; Talati R; Ghatak A; Kluger J;
Europace; 2009 Jul; 11(7):892-5. PubMed ID: 19351630
[TBL] [Abstract][Full Text] [Related]
16. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
[TBL] [Abstract][Full Text] [Related]
17. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.
Schreiber D; Rostock T; Fröhlich M; Sultan A; Servatius H; Hoffmann BA; Lüker J; Berner I; Schäffer B; Wegscheider K; Lezius S; Willems S; Steven D
Circ Arrhythm Electrophysiol; 2015 Apr; 8(2):308-17. PubMed ID: 25744570
[TBL] [Abstract][Full Text] [Related]
18. Dofetilide: a new pure class III antiarrhythmic agent.
Falk RH; Decara JM
Am Heart J; 2000 Nov; 140(5):697-706. PubMed ID: 11054613
[TBL] [Abstract][Full Text] [Related]
19. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
Khitri AR; Aliot EM; Capucci A; Connolly SJ; Crijns H; Hohnloser SH; Kulakowski P; Roy D; Radzik D; Kowey PR
J Cardiovasc Electrophysiol; 2012 May; 23(5):462-72. PubMed ID: 22171925
[TBL] [Abstract][Full Text] [Related]
20. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation.
Huang HD; Waks JW; Steinhaus DA; Zimetbaum P
Heart Rhythm; 2016 Jul; 13(7):1410-7. PubMed ID: 26921760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
